#Australia #Melbourne #CE Mark #4DMedical #CT:VQ™

4DMedical Receives CE Mark for CT:VQ™

4DMedical Limited, a pioneering leader in cardiothoracic imaging software, has officially announced that their revolutionary imaging technology, CT:VQ™, has been awarded CE Mark certification. This significant milestone not only facilitates the commercial launch of CT:VQ™ across the expansive European Union healthcare market but also signifies a notable advancement in the realm of non-invasive lung function diagnostics.

The Significance of the CE Mark

The CE Mark serves as a certificate of compliance with European health, safety, and environmental standards, which allows medical devices and technologies to be commercially distributed within the EU. This certification is a stepping stone for 4DMedical as they prepare to introduce CT:VQ™ to one of the largest medical imaging markets globally, characterized by advanced infrastructure and a health-conscious population of over 450 million.

Andreas Fouras, the CEO and founder of 4DMedical, highlighted that “The CE certification for CT:VQ™ represents a significant milestone that opens access to one of the largest and most sophisticated healthcare markets in the world.” With this certification, 4DMedical aims to leverage the EU's highly developed hospital imaging infrastructure and extensive existing CT equipment.

What is CT:VQ™?

CT:VQ™ is groundbreaking technology designed to merge the anatomical precision of common CT scans with functional ventilation-perfusion mapping. This combination allows clinicians to obtain quantitative insights into lung function without the need for contrast agents, which can be cumbersome and carry risks associated with radiation exposure. By using routine non-contrast CT scans, CT:VQ™ generates detailed ventilation and perfusion maps that highlight regional lung functionality. This advancement addresses a critical gap in respiratory imaging that has traditionally prioritized structural over functional assessments.

Furthermore, the technology integrates seamlessly with current clinical workflows by fitting into the existing CT infrastructures at major healthcare facilities. This ease of integration presents a significant advantage over conventional nuclear medicine techniques, which often face challenges related to the availability of radiotracers, operational complexity, and logistical issues.

Funding and Expansion Efforts

Alongside the CE certification announcement, 4DMedical secured a substantial investment of AUD 83 million through a private placement. This capital infusion is aimed at bolstering their growth initiatives, particularly expanding the market presence of CT:VQ™ throughout Europe. Such funding underscores the confidence investors have in 4DMedical's innovative approach to cardiothoracic imaging and sets a solid foundation for the company’s ambitious expansion plans.

The company has already seen increased interest in the United States, where CT:VQ™ is currently in use at prestigious medical institutions, including Stanford and the Mayo Clinic. The successful initial implementation at these major centers further validates the technology's potential impact and paves the way for its acceptance and adoption in Europe.

A Future of Enhanced Lung Function Diagnostics

The implementation of CT:VQ™ in Europe is not merely a commercial objective; it addresses a pressing clinical need across multiple healthcare systems. By overcoming the limitations associated with nuclear VQ scanning, such as the constraints posed by radiotracers and the complexity of operations, CT:VQ™ stands to revolutionize how respiratory conditions are diagnosed and monitored.

4DMedical is poised to drive partnerships and collaborations with leading European hospitals and clinical professionals to foster wider adoption of CT:VQ™, helping to pave the way for improved patient care in the diagnosis and management of pulmonary diseases.

In conclusion, with CE Mark certification received and significant investment secured, 4DMedical is not just ready to launch CT:VQ™ into the European market; it’s primed to lead a transformative shift in pulmonary healthcare diagnostics throughout the region.